SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
27 juin 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications of Efficacy in Assessable Patients at Multiple Dose...
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo
08 juin 2022 08h00 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel...
SELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
02 juin 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range...
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
26 mai 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a...
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
12 mai 2022 16h12 HE
|
SELLAS Life Sciences Group, Inc.
- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone...
SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
26 avr. 2022 08h30 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
11 avr. 2022 08h15 HE
|
SELLAS Life Sciences Group, Inc.
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) --...
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
06 avr. 2022 07h00 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
05 avr. 2022 16h51 HE
|
SELLAS Life Sciences Group, Inc.
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial...
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
31 mars 2022 21h03 HE
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...